Lung Cancer
Web Exclusives | April 2, 2021
Positive findings from this study support channeling additional resources into telemedicine care for lung cancer, and into future randomized controlled trials to verify effectiveness.
Web Exclusives | April 2, 2021
The COVID-19 pandemic has highlighted how critical it is to maintain resilience and flexibility of the healthcare system and healthcare providers.
Web Exclusives | April 2, 2021
Clinical data are highlighted, providing an understanding of the benefits of treatment with tyrosine kinase inhibitors.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Treatment with dabrafenib and trametinib produced similar benefits in pretreated and treatment-naïve patients.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
US Food and Drug Administration–approved capmatinib is an effective second-line treatment for patients with MET exon 14–mutated NSCLC.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
First-line treatment with ramucirumab plus erlotinib in patients with EGFR-mutated metastatic NSCLC was associated with superior progression-free survival compared with erlotinib plus placebo.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Lorlatinib is associated with longer progression-free survival and a higher overall and intracranial response rates among patients with previously untreated, advanced ALK-positive NSCLC.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Selpercatinib and pralsetinib are US Food and Drug Administration–approved treatment options for patients with RET fusion–positive NSCLC.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
[Fam-]trastuzumab deruxtecan shows promising clinical activity with a high and durable response rate in patients with HER2-mutated NSCLC.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Treatment with gefitinib in the adjuvant setting is associated with enhanced quality of life in patients with early-stage NSCLC and EGFR mutations.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512